Armistice Capital’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Armistice Capital’s Portfolio SXTP Stock Details SXTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,947	Closed	-$128K	–	282
2024 Q4	$128K	Buy	+4,947	New	+$109K	﹤0.01%	198

Other funds holding SXTP

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SHF

Safe Harbor Fiduciary Pensacola, Florida $105M AUM

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital's SXTP Position: Q1 2025 in Review

Armistice Capital sold out of 60 Degrees Pharmaceuticals (SXTP) in Q1 2025, closing a stake of 4,947 shares — an estimated $128K sold.

Armistice Capital first reported a position in SXTP in Q4 2024 and held it in 1 quarter. The position peaked at $128K in Q4 2024. 6 funds tracked by Wall St. Rank hold SXTP as of Q1 2025.

Armistice Capital reported no remaining 60 Degrees Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Armistice Capital sold 4,947 60 Degrees Pharmaceuticals shares in Q1 2025, an estimated $128K.
Armistice Capital first reported a position in 60 Degrees Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Armistice Capital's 60 Degrees Pharmaceuticals position peaked at $128K in Q4 2024.
6 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q1 2025.

Based on Armistice Capital's 13F filing for Q1 2025, filed 15 May 2025.